Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Eur J Med Chem ; 220: 113533, 2021 Aug 05.
Article in English | MEDLINE | ID: mdl-34049262

ABSTRACT

The selective serotonin reuptake inhibitors (SSRIs), acting at the serotonin transporter (SERT), are one of the most widely prescribed antidepressant medications. All five approved SSRIs possess either fluorine or chlorine atoms, and there is a limited number of reports describing their analogs with heavier halogens, i.e., bromine and iodine. To elucidate the role of halogen atoms in the binding of SSRIs to SERT, we designed a series of 22 fluoxetine and fluvoxamine analogs substituted with fluorine, chlorine, bromine, and iodine atoms, differently arranged on the phenyl ring. The obtained biological activity data, supported by a thorough in silico binding mode analysis, allowed the identification of two partners for halogen bond interactions: the backbone carbonyl oxygen atoms of E493 and T497. Additionally, compounds with heavier halogen atoms were found to bind with the SERT via a distinctly different binding mode, a result not presented elsewhere. The subsequent analysis of the prepared XSAR sets showed that E493 and T497 participated in the largest number of formed halogen bonds. The XSAR library analysis led to the synthesis of two of the most active compounds (3,4-diCl-fluoxetine 42, SERT Ki = 5 nM and 3,4-diCl-fluvoxamine 46, SERT Ki = 9 nM, fluoxetine SERT Ki = 31 nM, fluvoxamine SERT Ki = 458 nM). We present an example of the successful use of a rational methodology to analyze binding and design more active compounds by halogen atom introduction. 'XSAR library analysis', a new tool in medicinal chemistry, was instrumental in identifying optimal halogen atom substitution.


Subject(s)
Fluoxetine/pharmacology , Fluvoxamine/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin Plasma Membrane Transport Proteins/metabolism , Dose-Response Relationship, Drug , Fluoxetine/chemical synthesis , Fluoxetine/chemistry , Fluvoxamine/chemical synthesis , Fluvoxamine/chemistry , Humans , Ligands , Models, Molecular , Molecular Structure , Selective Serotonin Reuptake Inhibitors/chemical synthesis , Selective Serotonin Reuptake Inhibitors/chemistry , Structure-Activity Relationship
2.
Zhejiang Da Xue Xue Bao Yi Xue Ban ; 32(5): 441-2, 2003 10.
Article in Chinese | MEDLINE | ID: mdl-14610748

ABSTRACT

OBJECTIVE: To modify the synthetic method of fluvoxamine. METHODS: Fluvoxamine was synthesized from 4-trifluoromethylbenzonitrile by the steps of Grignard reaction, hydrolysis and oximation. RESULT: The chemical structure of the synthesized product was confirmed by (1)HNMR, and the total yield reached to 36.16%. CONCLUSION: The results indicate that the synthetic route is practical.


Subject(s)
Fluvoxamine/chemical synthesis , Selective Serotonin Reuptake Inhibitors/chemical synthesis
3.
Appl Radiat Isot ; 48(6): 749-54, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9204526

ABSTRACT

5-Methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone-O-(2-aminoethyl)oxi me (fluvoxamine), a potent clinically used antidepressant, was labelled with carbon-11 (t1/2 = 20.4 min) as a potential radioligand for the non-invasive assessment of serotonin uptake sites in the human brain with positron emission tomography (PET). The two-step radiochemical synthesis consisted of O-methylation of an amino-protected desmethyl precursor with [11C]methyl iodide under mild conditions in the presence of tetrabutylammonium hydroxide in acetonitrile, followed by deprotection with trifluoroacetic acid. 5-[11C]Methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone-O-(2-aminoethy l) oxime was obtained in > 98% radiochemical purity in 40 min with a radiochemical yield of 4 +/- 2% (non-decay corrected) and a specific radioactivity of 1 +/- 0.5 Ci/mumol. 5-Hydroxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone-O-[2- (tert-butoxycarbonylamino)ethyl]oxime, the precursor for the radiosynthesis of [11C]fluvoxamine, was prepared by a convenient three-step synthesis from the pharmaceutical form of fluvoxamine maleate by converting it into the free base, demethylation by trimethyliodosilane and introduction of the BOC-protective group with di-tert-butyl dicarbonate.


Subject(s)
Fluvoxamine/analogs & derivatives , Selective Serotonin Reuptake Inhibitors/chemical synthesis , Binding Sites , Brain/metabolism , Carbon Radioisotopes , Fluvoxamine/chemical synthesis , Fluvoxamine/metabolism , Fluvoxamine/pharmacology , Humans , Methods , Methylation , Radioligand Assay , Serotonin/metabolism , Selective Serotonin Reuptake Inhibitors/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Tomography, Emission-Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...